| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MINA |
| Uniprot No | Q8IUF8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-465aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MPKKAKPTGS GKEEGPAPCK QMKLEAAGGP SALNFDSPSS LFESLISPIK TETFFKEFWE QKPLLIQRDD PALATYYGSL FKLTDLKSLC SRGMYYGRDV NVCRCVNGKK KVLNKDGKAH FLQLRKDFDQ KRATIQFHQP QRFKDELWRI QEKLECYFGS LVGSNVYITP AGSQGLPPHY DDVEVFILQL EGEKHWRLYH PTVPLAREYS VEAEERIGRP VHEFMLKPGD LLYFPRGTIH QADTPAGLAH STHVTISTYQ NNSWGDFLLD TISGLVFDTA KEDVELRTGI PRQLLLQVES TTVATRRLSG FLRTLADRLE GTKELLSSDM KKDFIMHRLP PYSAGDGAEL STPGGKLPRL DSVVRLQFKD HIVLTVLPDQ DQSDETQEKM VYIYHSLKNS RETHMMGNEE ETEFHGLRFP LSHLDALKQI WNSPAISVKD LKLTTDEEKE SLVLSLWTEC LIQVV |
| 预测分子量 | 55 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与MINA(Myc-Induced Nuclear Antigen)重组蛋白相关的文献摘要示例(注：文献为示例性质，非真实引用)：
---
1. **《Structural insights into MINA53-mediated ribosome quality control》**
- **作者**: Tanaka K. et al.
- **摘要**: 本研究解析了MINA重组蛋白的晶体结构，揭示其作为核糖体相关去甲基酶的功能，通过调控组蛋白修饰参与核糖体RNA加工及细胞增殖调控。
2. **《MINA regulates MYC-driven tumorigenesis through ribosomal RNA methylation》**
- **作者**: Zhou Y. et al.
- **摘要**: 文章证明MINA重组蛋白通过催化28S rRNA的甲基化修饰，影响核糖体生物合成，从而调控MYC依赖性肿瘤细胞的生长和转移。
3. **《Functional characterization of recombinant MINA protein in cell cycle progression》**
- **作者**: Lee S. et al.
- **摘要**: 通过体外表达MINA重组蛋白，研究发现其通过抑制p53通路促进细胞周期G1/S期转换，提示其在癌症治疗中的潜在靶点价值。
---
**说明**：MINA(又称MINA53或NO66)是JmjC家族去甲基酶，参与表观遗传调控和癌症发展。实际研究中建议通过PubMed或Web of Science以关键词“MINA recombinant protein”“MINA53 structure/function”检索最新文献。
**Background of MINA Recombinant Protein**
The MINA protein, also known as MYC-induced nuclear antigen (MINA/NO66), is a conserved JmjC domain-containing protein implicated in diverse cellular processes, including ribosome biogenesis, epigenetic regulation, and cell cycle control. Initially identified as a MYC-responsive gene, MINA belongs to the JHDM (Jumonji C-domain-containing histone demethylase) family, though its enzymatic activity remains debated. Structurally, MINA contains a catalytic JmjC domain and a zinc finger motif, enabling interactions with ribosomal RNA (rRNA) and chromatin-modifying complexes. Studies suggest it regulates 18S rRNA processing and influences histone H3K36 demethylation, linking it to transcriptional and translational regulation.
Recombinant MINA protein is produced via genetic engineering, typically using bacterial (e.g., *E. coli*) or mammalian expression systems, to ensure high purity and functionality. Its recombinant form enables precise study of MINA's biochemical properties, substrate specificity, and interactions. Researchers utilize it to explore MINA's role in diseases, particularly cancer, where dysregulated MINA expression correlates with tumor progression, metabolic reprogramming, and therapy resistance. For example, MINA overexpression has been observed in glioblastoma, breast cancer, and leukemia, often associated with poor prognosis.
Additionally, MINA recombinant protein aids in drug discovery, serving as a target for small-molecule inhibitors aiming to modulate its activity. Challenges include resolving its dual roles in ribosome biology and epigenetic regulation, as well as clarifying conflicting reports about its demethylase activity. Current research focuses on its tissue-specific functions, post-translational modifications (e.g., phosphorylation), and crosstalk with signaling pathways like MYC and mTOR.
Overall, MINA recombinant protein serves as a critical tool for dissecting its multifaceted roles in health and disease, with potential applications in developing targeted therapies for cancers and ribosomopathies.
×
